Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00506675 · ClinicalTrials.gov registry record · Phase 3
Combined Patching-Atropine for Residual Amblyopia
A Phase 3 study, sponsored by Jaeb Center for Health Research.
- Terminated
- Registry status
- Phase 3
- Development phase
- 55
- Enrollment target
NCT00506675 is a Phase 3 study that was terminated before completion, run by Jaeb Center for Health Research. The registered enrollment target is 55 participants.
The verdict
NCT00506675, a Phase 3 study, was terminated before completion, sponsored by Jaeb Center for Health Research.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 55 participants
- Enrollment target
Study Summary
This study is designed to evaluate the effectiveness of treatment of residual amblyopia in children ages 3 to \< 10 years with visual acuity of 20/32 to 20/63 in the amblyopic eye. The study is a randomized clinical trial comparing intensive treatment (42 hours per week of patching plus daily atropine) with a control group that will have rapid weaning of existing treatment followed by spectacle correction only (if needed). The primary objective is to determine if this intensive treatment will improve visual acuity in patients with residual amblyopia. The primary outcome assessment is amblyopic eye visual acuity at 10 weeks. The primary analytic approach for the amblyopic eye acuity will be a treatment group comparison of the proportion of patients with at least two lines of visual acuity improvement.
Interventions
- DRUG Atropine
- DEVICE Patching
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00506675
The ClinicalTrials.gov registry entry for NCT00506675 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atropine is the first listed.
NCT00506675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00506675 about?
NCT00506675 is a clinical study titled "Combined Patching-Atropine for Residual Amblyopia". This study is designed to evaluate the effectiveness of treatment of residual amblyopia in children ages 3 to \< 10 years with visual acuity of 20/32 to 20/63 in the amblyopic eye. The study is a randomized clinical trial comparing intensive treatment (42 hours per week of patching plus daily atropi...
What is the current status of trial NCT00506675?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 55 participants. The study started on 2007-10. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00506675?
The interventions under investigation include: Atropine (DRUG), Patching (DEVICE).
Who is sponsoring clinical trial NCT00506675?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.